Mirum Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating

By Investor's Business Daily   |   2 years ago
Mirum Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating

Discover top growth stocks using the IBD Screen Of The Day. The RS Rating assesses a stock's price performance over 52 weeks compared to others. Focus on RS Ratings above 80 for big gains. Analyze Mirum Pharmaceuticals for potential breakout.

Read More

Did you find this insightful?